Imatinib Eugia (Imatinib)

Imatinib blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By inhibiting these enzymes, it stops downstream signaling pathways that promote cell division and survival, leading to apoptosis of cancer cells that rely on these kinases.

The exact dosage of Imatinib Eugia is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, weight, renal and hepatic function, and response to therapy. Dosing regimens are individualized and should follow the prescriber’s instructions.

Imatinib is classified as Pregnancy Category D, indicating evidence of fetal risk. It should not be used during pregnancy unless the potential benefit justifies the risk. Breastfeeding is not recommended while on Imatinib because the drug can be excreted in milk and may affect the infant.

To place an order, submit an enquiry on the Imatinib Eugia product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first targeted tyrosine‑kinase inhibitor approved for CML and remains a standard of care. Newer agents such as dasatinib or nilotinib may offer different potency or side‑effect profiles, but Imatinib’s long‑term safety data and cost‑effectiveness make it a widely used first‑line option.

Imatinib Eugia should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from excess moisture and direct sunlight to maintain stability throughout its shelf life.

Imatinib Eugia is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not crushed or chewed, unless the prescriber provides specific instructions for a different formulation.

Serious risks include hepatotoxicity, severe neutropenia, cardiac failure, pulmonary hypertension, and rare severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for liver enzymes, blood counts and cardiac function, and any concerning symptoms reported promptly.

Imatinib is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. It should also be avoided in pregnant women unless absolutely necessary, and used with caution in individuals with pre‑existing liver disease, heart failure, or severe infections.